News

December 13, 2018

CD64 Levels in Neutrophils Distinguish Infection From Active Disease in AAV, Lupus, Study Reports

News

Elevated levels of the CD64 protein on the surface of neutrophils – a type of immune cell – accurately distinguishes bacterial infection from disease flares in patients with ANCA-associated ... Read more

December 11, 2018

ANCA-associated Vasculitis Can Sometimes Manifest as Progressive Lung Disease, Case Report Suggests

News

In rare cases, ANCA-associated vasculitis (AAV) presents as an interstitial lung disease with a pattern of usual interstitial pneumonia several years before the clinical onset of vasculitis, a case report ... Read more

December 4, 2018

Early, Severe Infections Strongly Predict Mortality in Older Patients with Kidney Inflammation, Study Shows

News

The occurrence of a severe infection during the first month of care is a strong predictor of one-year mortality among patients 65 and older with ANCA-associated renal vasculitis — ... Read more

November 29, 2018

Early Disease Status Predicts Long-term Outcomes in AAV Patients, Study Suggests

News

Disease status at three and six months seems to predict long-term survival and kidney failure in patients with ANCA-associated vasculitis (AAV), a study shows. These findings suggest that early disease ... Read more

November 27, 2018

Plasma Exchange Not Seen to Lessen Risk of Death or Kidney Failure in Severe ANCA Vasculitis Patients in Phase 3 Trial

News

Plasma exchange — a procedure that removes plasma from the blood and replaces it with a donor-derived substitute — does not lessen a risk of end-stage renal disease (ESRD) ... Read more

November 20, 2018

Rituxan’s Efficacy May Be Linked to It Blocking How B-cells and Certain T-cells Interact, Study Says

News

Blocking the interaction between immune B-cells and CD8-positive T-cells may be what makes Rituxan (rituximab) an effective treatment for ANCA-associated vasculitis (AAV), a study reports. Findings of the study, “B cell ... Read more

November 15, 2018

Many ANCA-associated Vasculitis Patients Develop Hypersensitivity to Azathioprine, Study Shows

News

Nearly one in 10 ANCA-associated vasculitis (AAV) patients receiving azathioprine as a maintenance treatment for their condition develop hypersensitivity to the therapy, which manifests as whole body inflammation and skin eruptions, ... Read more

November 13, 2018

Cyclophosphamide and Rituxan May Safely Treat AAV Patients During Pregnancy, Study Finds

News

Standard therapies used to ANCA-associated vasculitis (AAV), like cyclophosphamide or Rituxan (rituximab), appear to be of benefit in patients who are pregnant, a literature review suggests. The study, “Successful treatment ... Read more

November 8, 2018

Calprotectin Blood Levels May Work as Biomarker for Tailoring Maintenance Treatments in AAV Patients

News

Levels of calprotectin in the blood correlate with markers of disease activity and a worsening in kidney function in ANCA-associated vasculitis patients, researchers in Spain report. The study, “Calprotectin as ... Read more

November 6, 2018

Rare SLE-AAV Overlap Syndrome May Cause Stroke, Case Report Shows

News

While rare, ANCA-associated vasculitis (AAV) may overlap with systemic lupus erythematosus (SLE) — the most common form of lupus — and manifest as an hemorrhagic stroke caused by a weakened ... Read more

Pin It on Pinterest